Explore the Agenda
7:00 am Morning Registration & Breakfast
7:45 am Ice Breaker
Break the ice before the science begins. Join your table for a light hearted, TRP-themed networking activity designed to get conversations flowing, strengthen connections and maximise your networking opportunities throughout the summit.
7:55 am Chair’s Opening Remarks
Winning Global Regulatory Alignment to De Risk, Accelerate & Commercialise TRPs Worldwide
8:00 am Radioligand Therapy as First Line Care: A Patient Story of Survival & Life Beyond Diagnosis
- Showcasing a patient journey in which RLT was the first and only cancer treatment to highlight real world impact on life beyond disease
- Exploring how receiving RLTs without prior therapies shaped long term quality of life, independence, and the ability to return to meaningful personal and professional activities.
- Bringing the patient voice into the scientific discussion by reflecting on what outcomes mattered most beyond clinical response, treatment burden, and survival statistics.
8:20 am Panel Discussion: The Industry Perspective on Navigating the Evolving Global Regulatory CMC Landscape for Targeted Radiopharmaceuticals
- Understanding how evolving global regulatory expectations across manufacturing, comparability, isotope supply and control strategy are reshaping the development and commercialisation pathway for targeted radiopharmaceuticals
- Exploring where regulatory fragmentation continues to create challenges across multinational TRP programs and determining how industry leaders are building more globally aligned CMC strategies to reduce downstream delays
- Examining how leading developers are proactively approaching scalability, manufacturing readiness, and supply resilience earlier in development to strengthen long-term regulatory and commercial success
9:00 am Regulatory Leaders Fireside Chat: Regulatory Perspectives on the Future of Radiopharmaceutical Development: Where Can Greater International Alignment Enable Faster, More Predictable TRP Development
- Examining how regulatory agencies are adapting to the increasing complexity and pace of radiopharmaceutical innovation
- Understanding the unique quality, manufacturing and safety considerations associated with radiopharmaceutical products compared with conventional medicines
- Exploring where earlier dialogue between developers and regulators can help de-risk development and streamline regulatory interactions
- Sharing perspectives on the priorities required to support future innovation while maintaining robust standards for patient safety and product quality
9:30 am Evolution of International Transport Regulations and their application to Radiopharmaceuticals: Balancing Safety, Compliance & Commercial Reality
- Understanding how international transport regulations are developed through the IAEA and implemented across international/national regulatory frameworks to govern the safe movement of radioactive materials
- Discussion about current practices, feedback on areas of non-compliance within the UK and where/how to get advice and guidance on compliance.
- Exploring the latest updates to the IAEA SSR-6 regulations and identifying aspects which have possible implications for radiopharmaceutical developers, manufacturers and logistics providers
10:00 am Speed Networking – How it Works
10:05 am Speed Networking
A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximise your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.
10:45 am Morning Break & Networking
Discovery & Preclinical Track
Discovery & Preclinical
Beyond Isotope Access: Aligning Radionuclide Selection with Clinical Applicability, Supply Reality & Commercial Feasibility
11:00 am Does Every Target Need the Same Radionuclide? Rethinking Isotope Selection for the Next Generation of Radiopharmaceuticals
Chief Scientific Officer, RadAlliance Therapeutics Inc
- Discovering why radionuclide selection should be driven by target biology, tumour characteristics and pharmacokinetics rather than platform familiarity
- Examining how different isotopes may influence therapeutic index, dosimetry, manufacturability and ultimately clinical success across diverse target classes
- Sharing lessons from designing next-generation theranostic programmes where isotope selection is considered alongside target selection from the earliest stages
11:30 am Session Reserved for Navigo Proteins
11:45 am Roundtable Discussion: Is Actinium-225 Ready for Mainstream Clinical Adoption? Balancing Scientific Promise with Development Reality
Chief Technology Officer, Nuclide Therapeutics
- Evaluating where Actinium-225 offers meaningful clinical advantages over established beta-emitting radionuclides to maximise patient benefit
- Overcoming isotope supply, manufacturing and infrastructure constraints to enable sustainable clinical development and future commercialisation
- Optimising target selection, dosimetry and therapeutic index to improve efficacy while minimising off-target toxicity
Translational & Clinical Track
Supply Chain & CMC
12:30 pm Lunch Break
Discovery & Preclinical Track
Building Next-Generation Preclinical Models to Better Predict Toxicity, Clinical Translation & First-in-Human Readiness
1:30 pm Re-Engineering the Therapeutic Window: Can Pre- Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
Vice President - Chemistry, Manufacturing & Control, OncoOne
- Determining how pre-targeting strategies separate tumour targeting from radionuclide delivery to improve tumour-tobackground ratios and reduce normal tissue exposure
- Examining the biological and translational challenges associated with conventional radiopharmaceutical approaches and where pre-targeting may offer a differentiated path forward
- Sharing lessons learned from candidate selection, platform optimisation and preclinical development when advancing nextgeneration pre-targeting technologies
2:00 pm Beyond Regulatory Requirements: Maximising the Value of Toxicology Studies to De-Risk Preclinical Development
CEO, Nuclide Therapeutics
- Understanding the critical role of toxicology studies in supporting safe and successful radiopharmaceutical development
- Exploring how developers can generate additional translational insights from toxicology programmes beyond minimum regulatory requirements
- Examining the unique considerations associated with designing and interpreting toxicology studies for radiopharmaceuticals
2:30 pm Theranostics in Practice: Building the Foundations for Successful Radiopharmaceutical Development
Executive Director - Translational Research & Core Facilities ,Program Sponsor, Theranostics, UHN
- Establishing integrated theranostics programmes that support translational research and clinical delivery
- Aligning imaging, clinical and operational expertise to accelerate radiopharmaceutical development
- Creating collaborative ecosystems that enable innovation from bench to bedside
Translational & Clinical Track
Supply Chain & CMC
3:00 pm Afternoon Break & Poster Session
Take this opportunity to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships whilst exploring the latest in radioligand therapy development and research advancements within poster presentations
From Late Line Success to Earlier Line Use: Redefining Radiopharmaceuticals as Transformative Frontline Cancer Therapies to Maximise Long-Term Patient Benefit & Disease Control
4:00 pm Integrating Radiopharmaceuticals into Standard of Care: Navigating Governance, Funding, Capacity, and Real-World Constraints
- Identifying the key barriers to integrating radiopharmaceuticals into standard care, including governance, funding models, regulatory frameworks, and system complexity
- Exploring how healthcare systems, industry, and regulators can collaborate to enable coordinated, scalable integration within existing constraints
- Assessing the infrastructure, workforce, and operational capacity required to support demand, including planning for variability between projected and real-world volumes
4:30 pm Building an Isotope Refinery: A New Class of Accelerator for the Theranostic Era
- The isotope supply challenge: the widening gap between clinical demand and what reactors, neutron sources and accelerators can produce today, and where that pressure is most acute for targeted radionuclide therapy
- The StandardX isotope production platform: how our FFA-type accelerator makes an isotope refinery possible, and what sets it apart as a new class of accelerator
- Progress so far and route to supply: milestones achieved to date, and the path ahead to commercial medical isotope supply
5:00 pm Panel Discussion: Why Are Big Pharma Betting on Targeted Radiopharmaceuticals?
- Exploring the scientific, clinical and commercial factors driving increasing investment into targeted radiopharmaceuticals from large pharmaceutical companies
- Comparing the evolution of the radiopharmaceutical landscape with the rapid growth of antibody-drug conjugates and identifying the key lessons that can be applied across modalities
- Debating whether radiopharmraceuticals are approaching a similar inflection point to ADCs and what challenges still need to be overcome to unlock broader adoption
5:30 pm Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?
- Identifying the scientific, clinical and commercial characteristics investors believe will differentiate tomorrow’s category leaders from an increasingly crowded pipeline
- Exploring which risks remain most significant to investment decisions, from manufacturing scalability and reimbursement to target differentiation and regulatory execution
- Evaluating the milestones that create the greatest enterprise value and discussing where capital should be deployed to maximise long-term commercial success